Genetic Variant Associated With Aggressive Prostate Cancer

The American Association of Cancer Researchers (AACR) is in the midst of its annual scientific research meeting in Denver Colorado. As interesting prostate cancer specific information becomes available I will try and share the news. One of the biggest concerns we face in prostate cancer is in deciding when a cancer needs to be treated. [...]

National Cancer Institute’s (NCI) Plan to Accelerate Cancer Research Announced

At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, National Cancer Institute (NCI) Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment. [...]

Long-Term Effects of Intermittent Androgen Suppression on Testosterone Recovery and Bone Mineral Density: Results of a 33-Month Observational Study

A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]

“Prostate Research, Imaging, and Men’s Education Act (PRIME)”

Senator Barbara Boxer Introduces Cancer-Related Legislation Senator Barbara Boxer (D-CA) has introduced two bills to improve research on prostate cancer and ovarian cancer. S. 756, the "Prostate Research, Imaging, and Men's Education Act (PRIME)" provides for prostate cancer imaging research and education. The reintroduced, S.755 Ovarian Cancer Biomarker Research Act is legislation to develop new [...]

A First Generation Bisphosphnate Increases Overall Survival in Metastatic Prostate Cancer

A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]

Go to Top